New drug tested for rapid control of damaging kidney disease
NCT ID NCT07163611
Summary
This study is testing a drug called obinutuzumab to see how quickly it can lower harmful antibodies in adults with a serious autoimmune kidney disease called membranous nephropathy. It will involve 20 patients who still have high protein in their urine despite standard care. The main goal is to see how fast the drug works and if it helps patients achieve remission while monitoring side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY - PLA2R INDUCED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nephrology, Radboud University Medical Center
RECRUITINGNijmegen, Netherlands
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.